COMPARISON OF UPFRONT ARAT THERAPY AND CAB THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER: A RETROSPECTIVE MULTICENTER STUDY

被引：0
|
作者：
Shiraishi, Yusuke
Tobe, Taisuke
Ueki, Hideto
Suzuki, Kotaro
Hara, Takuto
Terakawa, Tomoaki
Teishima, Jun
Nakano, Yuzo
Miyake, Hideaki
Fujisawa, Masato
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP60-10
引用
收藏
页码：E1003 / E1004
页数：2
相关论文
共 50 条
  • [31] Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer
    Sathianathen, Niranjan J.
    Philippou, Yiannis A.
    Kuntz, Gretchen M.
    Konety, Badrinath R.
    Gupta, Shilpa
    Lamb, Alastair D.
    Dahm, Philipp
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (10):
  • [32] Biomarker exploration of neoadjuvant therapy in metastatic/local hormone-sensitive prostate cancer
    Zhuang, J.
    Zhang, Y.
    EUROPEAN UROLOGY, 2021, 79 : S600 - S600
  • [33] Triplet Therapy: Entering the Metaverse of Metastatic Hormone-sensitive Prostate Cancer Treatment
    Dzimitrowicz, Hannah E.
    Armstrong, Andrew J.
    EUROPEAN UROLOGY, 2022, 82 (06) : 599 - 601
  • [34] Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?
    Thomas, C.
    Ohlmann, C-H
    UROLOGE, 2020, 59 (06): : 665 - 672
  • [35] Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 195 (01): : 94 - 94
  • [36] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
    Kai Ozaki
    Shingo Hatakeyama
    Shintaro Narita
    Kenichi Hata
    Takafumi Yanagisawa
    Toshikazu Tanaka
    Kyo Togashi
    Tomoko Hamaya
    Teppei Okamoto
    Hayato Yamamoto
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Takahiro Kimura
    Tomonori Habuchi
    Chikara Ohyama
    World Journal of Urology, 2023, 41 : 67 - 75
  • [37] Metastatic, hormone-sensitive prostate cancer: chemo-hormonal therapy for all?
    Miller, K.
    UROLOGE, 2018, 57 (08): : 958 - 959
  • [38] Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
    Ozaki, Kai
    Hatakeyama, Shingo
    Narita, Shintaro
    Hata, Kenichi
    Yanagisawa, Takafumi
    Tanaka, Toshikazu
    Togashi, Kyo
    Hamaya, Tomoko
    Okamoto, Teppei
    Yamamoto, Hayato
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Kimura, Takahiro
    Habuchi, Tomonori
    Ohyama, Chikara
    WORLD JOURNAL OF UROLOGY, 2023, 41 (01) : 67 - 75
  • [39] Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study
    Merseburger, Axel S.
    Chowdhury, Simon
    Bahl, Amit
    EUROPEAN UROLOGY, 2024, 86 (04) : 340 - 342
  • [40] Metastatic hormone-sensitive prostate cancer
    Gravis, Gwenaelle
    Salem, Naji
    Walz, Jochen
    BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
12345